Pomerantz LLP Investigates Securities Fraud Claims Against Sanara MedTech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy SMTI?
Source: PRnewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Sanara MedTech and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially lead to a class action lawsuit.
- Business Restructuring Decision: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, with management stating that this move was intended to reallocate resources to its core surgical business to enhance operational efficiency.
- Financial Loss Disclosure: Following the cessation of the THP program, Sanara reported a net loss of $31.2 million for Q3 2025, including a $26.5 million non-cash asset impairment charge directly related to the program's shutdown, highlighting the financial impact of the business adjustment.
- Stock Price Volatility: After the loss announcement on November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, reflecting market concerns regarding the company's future outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.400
Low
36.00
Averages
36.00
High
36.00
Current: 18.400
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanara MedTech Under Investigation for Securities Violations Impacting Shareholder Rights
- Legal Investigation Launched: The Schall Law Firm has initiated an investigation into Sanara MedTech, focusing on potential violations of securities laws that may harm shareholder rights, indicating possible issues with the company's transparency and compliance.
- Business Adjustment Impact: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, claiming the decision was made to reallocate resources to its core surgical business; however, this move may reflect underlying inefficiencies in the company's operations.
- Significant Financial Losses: In its Q3 2025 financial report, Sanara disclosed a net loss of $31.2 million from discontinued operations, including a $26.5 million charge related to the THP program, highlighting challenges in financial management and operational viability.
- Stock Price Plummet: Following the news, Sanara's shares fell by 24.7% on November 12, 2026, reflecting market pessimism regarding the company's future prospects, which could adversely affect its ability to raise capital and investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Sanara MedTech
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Sanara MedTech and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially lead to a class action lawsuit.
- Business Restructuring Decision: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, with management stating that this move was intended to reallocate resources to its core surgical business to enhance operational efficiency.
- Financial Loss Disclosure: Following the cessation of the THP program, Sanara reported a net loss of $31.2 million for Q3 2025, including a $26.5 million non-cash asset impairment charge directly related to the program's shutdown, highlighting the financial impact of the business adjustment.
- Stock Price Volatility: After the loss announcement on November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, reflecting market concerns regarding the company's future outlook.
See More
Sanara MedTech (SMTI) Q4 2025 Earnings Transcript
See More
Sanara MedTech Under Investigation for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial pressure during the business adjustment.
- Asset Impairment Loss: Following the THP program's shutdown, Sanara reported a non-cash asset impairment charge of $26.5 million, directly affecting the company's financial health and reflecting inadequate risk management in new product development.
- Stock Price Volatility: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11, demonstrating strong market concerns about the company's future prospects, which could undermine investor confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal liabilities and increase the compliance risks faced by the company.
See More
Investigation into Sanara MedTech for Alleged Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial strain during the business adjustment.
- Asset Impairment Loss: Following the cessation of the THP program, Sanara reported a noncash asset impairment charge of $26.5 million, which directly impacted the company's financial health and highlighted its vulnerability in market competition.
- Stock Price Plunge: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, severely undermining investor confidence and potentially complicating future financing efforts.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could further affect the company's reputation and shareholder interests, increasing future legal risks.
See More
Sanara MedTech to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sanara MedTech is set to announce its Q1 2026 financial results on May 12, 2026, before U.S. market opening, reflecting the company's ongoing development and market performance in the medical technology sector.
- Conference Call Details: On the same day, the company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly results ending March 31, 2026, with a Q&A session to enhance investor engagement.
- Replay Service Availability: Following the call, investors can access a telephonic replay by dialing 877-481-4010 (international: 919-882-2331), available until May 26, 2026, ensuring information accessibility.
- Product Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market, primarily selling products like CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, thereby strengthening its competitive position in North America.
See More
Sanara MedTech Under Investigation for Securities Violations Impacting Shareholder Rights
- Legal Investigation Launched: The Schall Law Firm has initiated an investigation into Sanara MedTech, focusing on potential violations of securities laws that may harm shareholder rights, indicating possible issues with the company's transparency and compliance.
- Business Adjustment Impact: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, claiming the decision was made to reallocate resources to its core surgical business; however, this move may reflect underlying inefficiencies in the company's operations.
- Significant Financial Losses: In its Q3 2025 financial report, Sanara disclosed a net loss of $31.2 million from discontinued operations, including a $26.5 million charge related to the THP program, highlighting challenges in financial management and operational viability.
- Stock Price Plummet: Following the news, Sanara's shares fell by 24.7% on November 12, 2026, reflecting market pessimism regarding the company's future prospects, which could adversely affect its ability to raise capital and investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Sanara MedTech
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Sanara MedTech and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially lead to a class action lawsuit.
- Business Restructuring Decision: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, with management stating that this move was intended to reallocate resources to its core surgical business to enhance operational efficiency.
- Financial Loss Disclosure: Following the cessation of the THP program, Sanara reported a net loss of $31.2 million for Q3 2025, including a $26.5 million non-cash asset impairment charge directly related to the program's shutdown, highlighting the financial impact of the business adjustment.
- Stock Price Volatility: After the loss announcement on November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, reflecting market concerns regarding the company's future outlook.
See More
Sanara MedTech (SMTI) Q4 2025 Earnings Transcript
See More
Sanara MedTech Under Investigation for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial pressure during the business adjustment.
- Asset Impairment Loss: Following the THP program's shutdown, Sanara reported a non-cash asset impairment charge of $26.5 million, directly affecting the company's financial health and reflecting inadequate risk management in new product development.
- Stock Price Volatility: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11, demonstrating strong market concerns about the company's future prospects, which could undermine investor confidence.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could lead to further legal liabilities and increase the compliance risks faced by the company.
See More
Investigation into Sanara MedTech for Alleged Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial strain during the business adjustment.
- Asset Impairment Loss: Following the cessation of the THP program, Sanara reported a noncash asset impairment charge of $26.5 million, which directly impacted the company's financial health and highlighted its vulnerability in market competition.
- Stock Price Plunge: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, severely undermining investor confidence and potentially complicating future financing efforts.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could further affect the company's reputation and shareholder interests, increasing future legal risks.
See More
Sanara MedTech to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sanara MedTech is set to announce its Q1 2026 financial results on May 12, 2026, before U.S. market opening, reflecting the company's ongoing development and market performance in the medical technology sector.
- Conference Call Details: On the same day, the company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly results ending March 31, 2026, with a Q&A session to enhance investor engagement.
- Replay Service Availability: Following the call, investors can access a telephonic replay by dialing 877-481-4010 (international: 919-882-2331), available until May 26, 2026, ensuring information accessibility.
- Product Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market, primarily selling products like CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, thereby strengthening its competitive position in North America.
See More
